Patients with locally advanced , recurrent , or metastatic NSCLC who had received at least one and no more than two prior systemic treatment regimens were randomized ( @:@ ) to a combination of docetaxel ( @ mg/m intravenous every @ days ) with or without PX-@ ( @ mg orally daily ; arms A and B , respectively ) .